This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Murray A. Raskind, MD; Elaine R. Peskind, MS; Jeffrey B. Halter, MD; David C. Jimerson, MD

Arch Gen Psychiatry. 1984;41(4):343-346.

Abstract
• Postmortem findings of decreased brain norepinephrine (NE) content and decreased locus ceruleus neuronal density have suggested a possible noradrenergic deficit in Alzheimer's disease (AD). We assessed CNS and peripheral noradrenergic function in patients with advanced AD, moderate AD, and age-matched normals by measuring NE and the NE metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in CSF and plasma. Subjects were drug free for at least two weeks. Plasma and CSF NE and MHPG levels were significantly higher in patients with advanced AD than in either patients with moderate AD or normal controls, while values in the patients with moderate AD did not differ from those in normal controls. These findings do not support either a central or peripheral noradrenergic deficit in AD. Rather, they suggest increased CNS and peripheral noradrenergic activity in advanced stages of the disease.

Author Affiliations
From the Departments of Psychiatry and Behavioral Sciences (Dr Raskind and Ms Peskind) and Medicine (Dr Halter), University of Washington School of Medicine, Seattle, and the Seattle/American Lake Veterans Administration Geriatric Research, Education and Clinical Center (Drs Raskind and Halter and Ms Peskind); and the Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Md (Dr Jimerson).

Footnotes
Accepted for publication Sept 12, 1983.

Reprint requests to Geriatric Research, Education and Clinical Center, Seattle Veterans Administration Medical Center, 1660 S Columbian Way, Seattle, WA 98108 (Dr Raskind).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Compensatory Changes in the Noradrenergic Nervous System in the Locus Ceruleus and Hippocampus of Postmortem Subjects with Alzheimer's Disease and Dementia with Lewy Bodies
Szot et al.
J. Neurosci. 2006;26:467-478.
ABSTRACT | FULL TEXT  

The Role of Norepinephrine in the Behavioral and Psychological Symptoms of Dementia
Herrmann et al.
J. Neuropsychiatry Clin. Neurosi. 2004;16:261-276.
ABSTRACT | FULL TEXT  

Role of Serotonin in the Behavioral and Psychological Symptoms of Dementia
Lanctôt et al.
J. Neuropsychiatry Clin. Neurosi. 2001;13:5-21.
ABSTRACT | FULL TEXT  

Increased Plasma Norepinephrine Response to Yohimbine in Elderly Men
Petrie et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2000;55:155M-159.
ABSTRACT | FULL TEXT  

Biologic Markers and Neurochemical Correlates of Agitation and Psychosis in Dementia
Kirby and Lawlor
J Geriatr Psychiatry Neurol 1995;8:S2-S7.
ABSTRACT  

Increased Sympathetic and Decreased Parasympathetic Cardiac Innervation in Patients With Alzheimer's Disease
Aharon-Peretz et al.
Arch Neurol 1992;49:919-922.
ABSTRACT  

Biologic Markers, Genetics, and Alzheimer's Disease
Small and Greenberg
Arch Gen Psychiatry 1988;45:945-947.
ABSTRACT